Topic:
M&A
Latest Headlines
Latest Headlines
Amgen forges Chinese JV for Vectibix
The China drug market is getting trickier but that is not stopping the big names of biotech and pharma from plowing ahead with tie-ups of various kinds to sell into the enormous market. Amgen today said it is ready to attack the Chinese market with one of its cancer drugs.
Sony sinks $10M into Israeli medical device incubator
As Sony works to build its presence in the medical device world, the Japanese giant is investing $10 million in Rainbow Medical, an Israeli incubator with portfolio companies that make stents, stimulators and other devices.
Report: ICU weighing billion-dollar sale
ICU Medical is considering selling itself, retaining advisers to find suitors and weigh offers that may soar past $1 billion.
UPDATED: Takeda beefs up new vaccines arm with $250M bolt-on buyout of Inviragen
A couple of months after moving its experimental dengue vaccine into the second phase of a mid-stage study, Fort Collins, CO-based Inviragen has been snapped up by Takeda in a $250 million deal.
Dx test maker Quidel gabs BioHelix for $10M-plus
The deal is done. Diagnostic test maker Quidel now officially owns BioHelix, a Beverly, MA maker of nucleic acid technology for molecular diagnostic tests. Quidel is paying $10 million in cash up front, plus more money depending on a number of development and sales milestones.
Minority Schering shareholders extract another €46 per share from Bayer
A group of minority Schering AG shareholders held out to the bitter end against what Bayer wanted to pay them for their shares, and they will now get the sweet deal they said they deserved.
Covidien predicts up to 11% sales growth at soon-to-be independent Mallinckrodt unit
Covidien unveiled its forecast for Mallinckrodt, the drug unit it plans to set free later this year. Percentage-wise, the expectations are strong: For the fiscal year ending on September 27, Covidien predicts sales growth of 7% to 11% compared with 2012.
Welsh CRO Simbec goes independent with new investment
CRO Simbec Research is using an investment from the Wales Life Sciences Investment Fund to acquire itself from the Canadian Altasciences Group, looking to expand its staff to more than 100 and chase new development deals around the world.
CRO Novotech picks up PE investment to expand in Asia
Australia's Novotech has sold off a 30% stake to private equity firm Mercury Capital, planning to use the money to spread its reach across Asia.
TFS buys Beardsworth to expand oncology trial work
Swedish CRO TFS is getting back to M&A, acquiring Beardsworth Consulting Group to bolster its capacity for oncology and vaccine clinical trials.
